U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H18F2N2O5
Molecular Weight 452.4069
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LUMACAFTOR

SMILES

CC1=CC=C(NC(=O)C2(CC2)C3=CC4=C(OC(F)(F)O4)C=C3)N=C1C5=CC=CC(=C5)C(O)=O

InChI

InChIKey=UFSKUSARDNFIRC-UHFFFAOYSA-N
InChI=1S/C24H18F2N2O5/c1-13-5-8-19(27-20(13)14-3-2-4-15(11-14)21(29)30)28-22(31)23(9-10-23)16-6-7-17-18(12-16)33-24(25,26)32-17/h2-8,11-12H,9-10H2,1H3,(H,29,30)(H,27,28,31)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206038Orig1s000lbl.pdf https://newdrugapprovals.org/tag/lumacaftor/

Lumacaftor (VX-809) is an investigational drug developed by the Massachusetts-based pharmaceutical company Vertex for the treatment of patients who suffer from cystic fibrosis (CF) and have the F508del mutation in the CF transmembrane conductance regulator (CFTR). Currently, lumacaftor is approved by the U.S. FDA as a combined oral treatment for CF in combination with Kalydeco (ivacaftor). Lumacaftor is commercialized by Vertex under the brand name Orkambi, and Kalydeco was approved in the United States in 2012. The lumacaftor/Kalydeco combo was approved by the FDA in July 2015 for patients ages 12 and older, while the use of lumacaftor alone is still being studied by Vertex. The mechanism of action of lumacaftor is based on the interference with the F508 CFTR. The chronic disease is caused by a mutation in the gene that controls the salt transportation in the cells, resulting in thick, sticky mucus in the respiratory, digestive, and reproductive systems. To address that genetic defect, lumacaftor helps correct the mutated genes with a novel therapeutic approach. Both lumicaftor and kalydeco work by correcting the misfolded CFTR protein, the root cause of the F508del mutation, which led to the approval of the combined treatment by the FDA. However, while kalydeco alone is also approved by the FDA, the use of lumacftor alone has not yet been approved.

Originator

Approval Year

2015
471
Targets

Targets

Primary TargetPharmacologyConditionPotency
Chaperone
14
Activator
1430
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Orkambi

Approved Use

ORKAMBI is a combination of lumacaftor and ivacaftor, a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator, indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.

Launch Date

2015
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
25 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206038s010lbl.pdf
400 mg 2 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LUMACAFTOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
198 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206038s010lbl.pdf
400 mg 2 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LUMACAFTOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
25.2 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206038s010lbl.pdf
200 mg 2 times / day steady-state, oral
dose: 200 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LUMACAFTOR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206038s010lbl.pdf
400 mg 2 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
LUMACAFTOR plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Other AEs: Cough, Headache...
Other AEs:
Cough (52.6%)
Headache (26.3%)
Rales (15.8%)
Productive cough (31.6%)
Dyspnoea (21.1%)
Respiratory tract disorders NEC (21.1%)
Fatigue (15.8%)
Fever (26.3%)
Nasal congestion (11.8%)
Oropharyngeal pain (10.5%)
Sinus congestion (5.3%)
Respiration abnormal (21.1%)
Haemoptysis (10.5%)
Constipation (5.3%)
Abdominal pain (5.3%)
Myalgia (5.3%)
Post-tussive vomiting (5.3%)
Nausea (5.3%)
Nasopharyngitis (10.5%)
Dizziness (5.3%)
Back pain (5.3%)
Abdominal pain upper (10.5%)
Sputum abnormal (5.3%)
Epistaxis (10.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
AEs

AEs

AESignificanceDosePopulation
Abdominal pain upper 10.5%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Epistaxis 10.5%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Haemoptysis 10.5%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Nasopharyngitis 10.5%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Oropharyngeal pain 10.5%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Nasal congestion 11.8%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Fatigue 15.8%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Rales 15.8%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Dyspnoea 21.1%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Respiration abnormal 21.1%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Respiratory tract disorders NEC 21.1%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Fever 26.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Headache 26.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Productive cough 31.6%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Abdominal pain 5.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Back pain 5.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Constipation 5.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Dizziness 5.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Myalgia 5.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Nausea 5.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Post-tussive vomiting 5.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Sinus congestion 5.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Sputum abnormal 5.3%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Cough 52.6%
200 mg 1 times / day steady, oral
Dose: 200 mg, 1 times / day
Route: oral
Route: steady
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
unhealthy, 25 years(range: 18–42 years)
n = 19
Health Status: unhealthy
Age Group: 25 years(range: 18–42 years)
Sex: M+F
Population Size: 19
Sources:
https://pubmed.ncbi.nlm.nih.gov/21825083
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1737

inhibitor
1587

inducer
781
inhibitor
1767
substrate
1217

inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2C19
1478

CYP2B6
810

CYP2C8
911

P-gp
1461

OATP1B1
788

OATP1B3
706
P-gp
1537

OATP1B1
406

OATP1B3
350
CYP1A2
701

CYP2B6
547
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2B6
1001
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP3A4
1925
 no
OATP1B1
803
 no
OATP1B3
715
 no
CYP2B6
1001
 yes
CYP2C19
1553
 yes
CYP2C8
965
 yes
CYP3A4
1925
 yes
P-gp
1650
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OATP1B1
406
 no
OATP1B3
350
 no
P-gp
1537
 no
CYP2D6
1217
 yes
CYP3A4
1737
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:90951
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:90951
ChemicalBook
CB32489655
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32489655
MolPort
MolPort-009-198-874
https://www.molport.com/shop/molecule-link/MolPort-009-198-874
Selleck Chemicals
VX-809
http://www.selleckchem.com/products/VX-809.html
ZINC
ZINC000064033452
http://zinc15.docking.org/substances/ZINC000064033452
eMolecules
32278074
https://www.emolecules.com/cgi-bin/more?vid=32278074
PubMed

PubMed

TitleDatePubMed
VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
2013 Oct
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.
2014 Jul
Patents

Patents

07659268
4
07956052
2
08324207
1
08507534
1
08507687
1
08552034
1
08653103
1
08716338
1
08742122
1
08816093
1
08846718
1
20080019915
1
20080113985
2
20080306062
2
20090170905
1
JP2013253111A
1

Sample Use Guides

In Vivo Use Guide
Adults and pediatric patients age 12 years and older: two tablets (each containing lumacaftor 200 mg/ivacaftor 125 mg) taken orally every 12 hours with fat-containing food.
Route of Administration: Oral
In Vitro Use Guide
Acute pretreatment of temperature-rescued F508del-CFTR in BHK Cells with 3uM Lumacaftor (VX-809) promotes channel activation
Name Type Language
LUMACAFTOR
DASH   INN   USAN   WHO-DD  
INN   USAN  
Official Name English
LUMACAFTOR [ORANGE BOOK]
Common Name English
VRT826809
Code English
VX-809
Code English
VRT-826809
Code English
Lumacaftor [WHO-DD]
Common Name English
LUMACAFTOR [MI]
Common Name English
VX809
Code English
3-(6-(1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)CYCLOPROPANE-1-CARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
Systematic Name English
ORKAMBI COMPONENT LUMACAFTOR
Brand Name English
BENZOIC ACID, 3-(6-(((1-(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)CYCLOPROPYL)CARBONYL)AMINO)-3-METHYL-2-PYRIDINYL)-
Common Name English
3-(6-(1-(2,2-DIFLUOROBENZO(D) (1,3)DIOXYL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID
Systematic Name English
lumacaftor [INN]
Common Name English
LUMACAFTOR COMPONENT OF ORKAMBI
Brand Name English
LUMACAFTOR [USAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 301610
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
EMA ASSESSMENT REPORTS ORKAMBI (AUTHORIZED: CYSTIC FIBROSIS)
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
FDA ORPHAN DRUG 434814
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
EU-Orphan Drug EU/3/14/1333
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
FDA ORPHAN DRUG 761720
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
WHO-ATC R07AX30
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
Code System Code Type Description
CAS
936727-05-8
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
NDF-RT
N0000184145
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY Chloride Channel Activation Potentiators [MoA]
FDA UNII
EGP8L81APK
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
ChEMBL
CHEMBL2103870
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
DRUG CENTRAL
5010
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
USAN
XX-134
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
DRUG BANK
DB09280
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
NDF-RT
N0000187063
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY Cytochrome P450 2C8 Inducers [MoA]
NDF-RT
N0000187064
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY Cytochrome P450 2B6 Inducers [MoA]
WIKIPEDIA
LUMACAFTOR
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
IUPHAR
7481
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
NDF-RT
N0000185504
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY Cytochrome P450 2C9 Inhibitors [MoA]
NDF-RT
N0000185607
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY Cytochrome P450 2C19 Inducers [MoA]
INN
9449
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
MERCK INDEX
m11859
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
NDF-RT
N0000190118
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY Cytochrome P450 3A Inducers [MoA]
RXCUI
1655922
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY RxNorm
EVMPD
SUB130518
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
NDF-RT
N0000185507
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY Cytochrome P450 2C9 Inducers [MoA]
CHEBI
90951
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
DAILYMED
EGP8L81APK
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
LACTMED
Lumacaftor and Ivacaftor
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
PUBCHEM
16678941
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID30239523
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
NDF-RT
N0000187062
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY Cytochrome P450 2C8 Inhibitors [MoA]
NCI_THESAURUS
C170136
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
SMS_ID
100000156577
Created by admin on Fri Dec 15 20:15:38 GMT 2023 , Edited by admin on Fri Dec 15 20:15:38 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of LUMACAFTOR
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966